NFKB1 and mantle cell lymphoma: Targeting XPO1 with the selective inhibitor selinexor was found to sensitize intrinsic ibrutinib-resistant MCL cell lines by preventing the nuclear export of NF-κB regulators and inhibiting NF-kB signaling [46].